AAHRPP Awards Accreditation to Organizations in US, China, and Republic of Korea - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
AAHRPP Awards Accreditation to Organizations in US, China, and Republic of Korea

Source: Company News Release

The Association for the Accreditation of Human Research Protection Programs today announced that it has awarded accreditation to five more organizations, including institutions in Seoul, Republic of Korea; Nanjing, China; Michigan; New York and Louisiana. The newly accredited organizations are:

  • Asan Medical Center, Seoul, Republic of Korea
  • First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing, China
  • McLaren Health Care Corporation, Flint, Mich.
  • North Shore-LIJ Health System, Manhasset, N.Y.
  • Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, La.

                                       
“These latest accreditations demonstrate the increasing recognition that AAHRPP accreditation is the mark of excellence for human research protection programs, here and around the globe,” said Elyse Summers, AAHRPP president and CEO. “AAHRPP accreditation signifies an organization’s commitment to the highest level of research protections—all to the benefit of the research participants we are pledged to protect.”

AAHRPP accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. Accreditation decisions are made quarterly. They continue at a steady pace, reflecting strong interest in every sector of the research enterprise, in the U.S. and abroad.

To date, AAHRPP has accredited organizations in 46 states, Canada, China, India, Mexico, Republic of Korea, Singapore and Taiwan. All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, more than 60 percent of U.S. research-intensive universities and 65 percent of U.S. medical schools are either AAHRPP accredited or have begun the accreditation process.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Company News Release,
Click here